Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Absence of p.R50X Pygm read-through in McArdle disease cellular models.

Tarrasó G, Real-Martinez A, Parés M, Romero-Cortadellas L, Puigros L, Moya L, de Luna N, Brull A, Martín MA, Arenas J, Lucia A, Andreu AL, Barquinero J, Vissing J, Krag TO, Pinós T.

Dis Model Mech. 2020 Jan 13;13(1). pii: dmm043281. doi: 10.1242/dmm.043281.

2.

Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy.

Poulsen NS, Madsen KL, Hornsyld TM, Eisum AV, Fornander F, Buch AE, Stemmerik MG, Ruiz-Ruiz C, Krag TO, Vissing J.

Mitochondrion. 2020 Jan;50:35-41. doi: 10.1016/j.mito.2019.10.005. Epub 2019 Oct 26.

PMID:
31669236
3.

Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment.

Laforêt P, Inoue M, Goillot E, Lefeuvre C, Cagin U, Streichenberger N, Leonard-Louis S, Brochier G, Madelaine A, Labasse C, Hedberg-Oldfors C, Krag T, Jauze L, Fabregue J, Labrune P, Milisenda J, Nadaj-Pakleza A, Sacconi S, Mingozzi F, Ronzitti G, Petit F, Schoser B, Oldfors A, Vissing J, Romero NB, Nishino I, Malfatti E.

Acta Neuropathol Commun. 2019 Oct 28;7(1):167. doi: 10.1186/s40478-019-0815-2.

4.

Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report.

Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD.

BMC Neurol. 2019 Oct 22;19(1):247. doi: 10.1186/s12883-019-1490-4.

5.

POPDC3 Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy.

Vissing J, Johnson K, Töpf A, Nafissi S, Díaz-Manera J, French VM, Schindler RF, Sarathchandra P, Løkken N, Rinné S, Freund M, Decher N, Müller T, Duno M, Krag T, Brand T, Straub V.

Ann Neurol. 2019 Dec;86(6):832-843. doi: 10.1002/ana.25620. Epub 2019 Oct 28.

PMID:
31610034
6.

Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model.

Real-Martinez A, Brull A, Huerta J, Tarrasó G, Lucia A, Martin MA, Arenas J, Andreu AL, Nogales-Gadea G, Vissing J, Krag TO, de Luna N, Pinós T.

Sci Rep. 2019 Mar 26;9(1):5116. doi: 10.1038/s41598-019-41414-8.

7.

Adaptations in Mitochondrial Enzymatic Activity Occurs Independent of Genomic Dosage in Response to Aerobic Exercise Training and Deconditioning in Human Skeletal Muscle.

Fritzen AM, Thøgersen FB, Thybo K, Vissing CR, Krag TO, Ruiz-Ruiz C, Risom L, Wibrand F, Høeg LD, Kiens B, Duno M, Vissing J, Jeppesen TD.

Cells. 2019 Mar 12;8(3). pii: E237. doi: 10.3390/cells8030237.

8.

IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity.

Hojman P, Brolin C, Nørgaard-Christensen N, Dethlefsen C, Lauenborg B, Olsen CK, Åbom MM, Krag T, Gehl J, Pedersen BK.

Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E940-E947. doi: 10.1152/ajpendo.00414.2018. Epub 2019 Feb 19.

PMID:
30779630
9.

Expanding the phenotype of filamin-C-related myofibrillar myopathy.

Borch JS, Eisum AV, Krag T, Vissing J.

Clin Neurol Neurosurg. 2019 Jan;176:30-33. doi: 10.1016/j.clineuro.2018.11.013. Epub 2018 Nov 19.

PMID:
30496909
10.

BAG3 myopathy is not always associated with cardiomyopathy.

Andersen AG, Fornander F, Schrøder HD, Krag T, Straub V, Duno M, Vissing J.

Neuromuscul Disord. 2018 Sep;28(9):798-801. doi: 10.1016/j.nmd.2018.06.019. Epub 2018 Jul 5.

PMID:
30061062
11.

Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts.

Witting N, Krag T, Werlauff U, Duno M, Oestergaard ST, Dahlqvist JR, Vissing J.

Muscle Nerve. 2018 Jun;57(6):1026-1030. doi: 10.1002/mus.26067. Epub 2018 Feb 5.

PMID:
29342313
12.

Clinical heterogeneity and phenotype/genotype findings in 5 families with GYG1 deficiency.

Ben Yaou R, Hubert A, Nelson I, Dahlqvist JR, Gaist D, Streichenberger N, Beuvin M, Krahn M, Petiot P, Parisot F, Michel F, Malfatti E, Romero N, Carlier RY, Eymard B, Labrune P, Duno M, Krag T, Cerino M, Bartoli M, Bonne G, Vissing J, Laforet P, Petit FM.

Neurol Genet. 2017 Dec 18;3(6):e208. doi: 10.1212/NXG.0000000000000208. eCollection 2017 Dec.

13.

Limb girdle muscular dystrophy due to mutations in POMT2.

Østergaard ST, Johnson K, Stojkovic T, Krag T, De Ridder W, De Jonghe P, Baets J, Claeys KG, Fernández-Torrón R, Phillips L, Topf A, Colomer J, Nafissi S, Jamal-Omidi S, Bouchet-Seraphin C, Leturcq F, MacArthur DG, Lek M, Xu L, Nelson I, Straub V, Vissing J.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):506-512. doi: 10.1136/jnnp-2017-317018. Epub 2017 Nov 24.

PMID:
29175898
14.

Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse.

Nielsen TL, Pinós T, Brull A, Vissing J, Krag TO.

Mol Genet Metab. 2018 Jan;123(1):21-27. doi: 10.1016/j.ymgme.2017.11.006. Epub 2017 Nov 21.

PMID:
29174367
15.

Glycogen Synthesis in Glycogenin 1-Deficient Patients: A Role for Glycogenin 2 in Muscle.

Krag TO, Ruiz-Ruiz C, Vissing J.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2690-2700. doi: 10.1210/jc.2017-00399.

PMID:
28453664
16.

Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T).

Oestergaard ST, Stojkovic T, Dahlqvist JR, Bouchet-Seraphin C, Nectoux J, Leturcq F, Cossée M, Solé G, Thomsen C, Krag TO, Vissing J.

Neurol Genet. 2016 Oct 11;2(6):e112. eCollection 2016 Dec.

17.

Differential glucose metabolism in mice and humans affected by McArdle disease.

Krag TO, Pinós T, Nielsen TL, Duran J, García-Rocha M, Andreu AL, Vissing J.

Am J Physiol Regul Integr Comp Physiol. 2016 Aug 1;311(2):R307-14. doi: 10.1152/ajpregu.00489.2015. Epub 2016 Jun 8.

18.

Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease.

Krag TO, Pinós T, Nielsen TL, Brull A, Andreu AL, Vissing J.

J Neuropathol Exp Neurol. 2016 May;75(5):441-54. doi: 10.1093/jnen/nlw018. Epub 2016 Mar 30.

PMID:
27030740
19.

Electroporation Enhanced Effect of Dystrophin Splice Switching PNA Oligomers in Normal and Dystrophic Muscle.

Brolin C, Shiraishi T, Hojman P, Krag TO, Nielsen PE, Gehl J.

Mol Ther Nucleic Acids. 2015 Dec 1;4:e267. doi: 10.1038/mtna.2015.41.

20.

A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans.

Krag TO, Vissing J.

J Neuropathol Exp Neurol. 2015 Dec;74(12):1137-46. doi: 10.1097/NEN.0000000000000260.

PMID:
26574668
21.

Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo-controlled crossover study.

Andersen G, Ørngreen MC, Preisler N, Jeppesen TD, Krag TO, Hauerslev S, van Hall G, Vissing J.

Am J Physiol Regul Integr Comp Physiol. 2015 Jan 15;308(2):R123-30. doi: 10.1152/ajpregu.00321.2014. Epub 2014 Nov 19.

22.

Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy.

Witting N, Kruuse C, Nyhuus B, Prahm KP, Citirak G, Lundgaard SJ, von Huth S, Vejlstrup N, Lindberg U, Krag TO, Vissing J.

Ann Neurol. 2014 Oct;76(4):550-7. doi: 10.1002/ana.24216. Epub 2014 Jul 15.

PMID:
25042931
23.

Muscle atrophy reversed by growth factor activation of satellite cells in a mouse muscle atrophy model.

Hauerslev S, Vissing J, Krag TO.

PLoS One. 2014 Jun 25;9(6):e100594. doi: 10.1371/journal.pone.0100594. eCollection 2014.

24.

A novel de novo mutation of the mitochondrial tRNAlys gene mt.8340G>a associated with pure myopathy.

Jeppesen TD, Duno M, Risom L, Wibrand F, Rafiq J, Krag T, Jakobsen J, Andersen H, Vissing J.

Neuromuscul Disord. 2014 Feb;24(2):162-6. doi: 10.1016/j.nmd.2013.08.004. Epub 2013 Aug 20.

PMID:
24161205
25.

Muscle biopsies off-set normal cellular signaling in surrounding musculature.

Krag TO, Hauerslev S, Dahlqvist JR, Vissing J.

Neuromuscul Disord. 2013 Dec;23(12):981-5. doi: 10.1016/j.nmd.2013.09.012. Epub 2013 Sep 30.

PMID:
24148530
26.

Protein turnover and cellular stress in mildly and severely affected muscles from patients with limb girdle muscular dystrophy type 2I.

Hauerslev S, Sveen ML, Vissing J, Krag TO.

PLoS One. 2013 Jun 28;8(6):e66929. doi: 10.1371/journal.pone.0066929. Print 2013.

27.

A new mutation of the fukutin gene causing late-onset limb girdle muscular dystrophy.

Riisager M, Duno M, Hansen FJ, Krag TO, Vissing CR, Vissing J.

Neuromuscul Disord. 2013 Jul;23(7):562-7. doi: 10.1016/j.nmd.2013.04.006. Epub 2013 Jun 6.

PMID:
23746544
28.

A pilot study of muscle plasma protein changes after exercise.

Dahlqvist JR, Voss LG, Lauridsen T, Krag TO, Vissing J.

Muscle Nerve. 2014 Feb;49(2):261-6. doi: 10.1002/mus.23909. Epub 2013 Aug 30.

PMID:
23716353
29.

Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression.

Witting N, Duno M, Petri H, Krag T, Bundgaard H, Kober L, Vissing J.

J Neurol. 2013 Aug;260(8):2084-93. doi: 10.1007/s00415-013-6934-y. Epub 2013 May 14.

PMID:
23670307
30.

Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy.

Hauerslev S, Ørngreen MC, Hertz JM, Vissing J, Krag TO.

Acta Neurol Scand. 2013 Sep;128(3):194-201. doi: 10.1111/ane.12109. Epub 2013 Feb 15.

PMID:
23410246
31.

Muscle regeneration in mitochondrial myopathies.

Krag TO, Hauerslev S, Jeppesen TD, Duno M, Vissing J.

Mitochondrion. 2013 Mar;13(2):63-70. doi: 10.1016/j.mito.2013.01.009. Epub 2013 Feb 1.

PMID:
23376095
32.

Resistance training in patients with limb-girdle and becker muscular dystrophies.

Sveen ML, Andersen SP, Ingelsrud LH, Blichter S, Olsen NE, Jønck S, Krag TO, Vissing J.

Muscle Nerve. 2013 Feb;47(2):163-9. doi: 10.1002/mus.23491. Epub 2012 Nov 21.

PMID:
23169433
33.

Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies.

Hauerslev S, Sveen ML, Duno M, Angelini C, Vissing J, Krag TO.

BMC Musculoskelet Disord. 2012 Mar 23;13:43. doi: 10.1186/1471-2474-13-43.

34.

Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity.

Krag TO, Hauerslev S, Sveen ML, Schwartz M, Vissing J.

Skelet Muscle. 2011 Oct 5;1(1):31. doi: 10.1186/2044-5040-1-31.

35.

Short- and long-term effects of endurance training in patients with mitochondrial myopathy.

Jeppesen TD, Dunø M, Schwartz M, Krag T, Rafiq J, Wibrand F, Vissing J.

Eur J Neurol. 2009 Dec;16(12):1336-9. doi: 10.1111/j.1468-1331.2009.02660.x. Epub 2009 May 27.

PMID:
19486129
36.

Endurance training improves fitness and strength in patients with Becker muscular dystrophy.

Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J.

Brain. 2008 Nov;131(Pt 11):2824-31. doi: 10.1093/brain/awn189. Epub 2008 Sep 6.

PMID:
18776212
37.

Phenotype and clinical course in a family with a new de novo Twinkle gene mutation.

Jeppesen TD, Schwartz M, Colding-Jørgensen E, Krag T, Hauerslev S, Vissing J.

Neuromuscul Disord. 2008 Apr;18(4):306-9. doi: 10.1016/j.nmd.2007.10.007.

PMID:
18396044
38.

No muscle involvement in myoclonus-dystonia caused by epsilon-sarcoglycan gene mutations.

Hjermind LE, Vissing J, Asmus F, Krag T, Lochmüller H, Walter MC, Erdal J, Blake DJ, Nielsen JE.

Eur J Neurol. 2008 May;15(5):525-9. doi: 10.1111/j.1468-1331.2008.02116.x. Epub 2008 Mar 18.

PMID:
18355305
39.

Heregulin-induced epigenetic regulation of the utrophin-A promoter.

Basu U, Gyrd-Hansen M, Baby SM, Lozynska O, Krag TO, Jensen CJ, Frödin M, Khurana TS.

FEBS Lett. 2007 Sep 4;581(22):4153-8. Epub 2007 Jul 23.

40.

Deletion of exon 16 of the dystrophin gene is not associated with disease.

Schwartz M, Dunø M, Palle AL, Krag T, Vissing J.

Hum Mutat. 2007 Feb;28(2):205.

PMID:
17226814
41.

Endurance training: an effective and safe treatment for patients with LGMD2I.

Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J.

Neurology. 2007 Jan 2;68(1):59-61.

PMID:
17200494
42.

Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.

Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J.

Brain. 2006 Dec;129(Pt 12):3402-12. Epub 2006 Jun 30.

PMID:
16815877
43.

Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.

Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS.

FASEB J. 2005 Apr;19(6):543-9.

PMID:
15791004
44.

Heregulin ameliorates the dystrophic phenotype in mdx mice.

Krag TO, Bogdanovich S, Jensen CJ, Fischer MD, Hansen-Schwartz J, Javazon EH, Flake AW, Edvinsson L, Khurana TS.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13856-60. Epub 2004 Sep 13.

45.

Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Bogdanovich S, Perkins KJ, Krag TO, Khurana TS.

J Mol Med (Berl). 2004 Feb;82(2):102-15. Epub 2003 Dec 12. Review.

PMID:
14673527
46.

Functional improvement of dystrophic muscle by myostatin blockade.

Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS.

Nature. 2002 Nov 28;420(6914):418-21.

PMID:
12459784
47.

Sp1 and the ets-related transcription factor complex GABP alpha/beta functionally cooperate to activate the utrophin promoter.

Gyrd-Hansen M, Krag TO, Rosmarin AG, Khurana TS.

J Neurol Sci. 2002 May 15;197(1-2):27-35.

PMID:
11997063
48.

Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy.

Krag TO, Gyrd-Hansen M, Khurana TS.

Acta Physiol Scand. 2001 Mar;171(3):349-58. Review.

PMID:
11412148
49.

Identification of genes that are differentially expressed in extraocular and limb muscle.

Niemann CU, Krag TO, Khurana TS.

J Neurol Sci. 2000 Oct 1;179(S 1-2):76-84.

PMID:
11054489
50.

90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1.

Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frödin M.

J Biol Chem. 1999 Sep 17;274(38):27168-76.

Supplemental Content

Support Center